

# Gastroesophageal Reflux disease - Pipeline Insight, 2021

<https://marketpublishers.com/r/G9CE394ED4BBEN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: G9CE394ED4BBEN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Gastroesophageal Reflux disease - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Gastroesophageal Reflux disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Gastroesophageal Reflux disease Understanding

#### Gastroesophageal Reflux disease: Overview

Gastro-oesophageal reflux disease (GORD) is a common condition, where acid from the stomach leaks up into the oesophagus (gullet). It usually occurs as a result of the ring of muscle at the bottom of the oesophagus becoming weakened. Read more about the causes of GORD. GORD causes symptoms such as heartburn and an unpleasant taste in the back of the mouth. It may just be an occasional nuisance for some people, but for others it can be a severe, lifelong problem. GORD can often be controlled with self-help measures and medication. Occasionally, surgery to correct the problem may be needed.

'Gastroesophageal Reflux disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastroesophageal Reflux disease pipeline landscape is provided which includes the disease overview and Gastroesophageal Reflux disease treatment guidelines. The assessment part of the report embraces, in depth Gastroesophageal Reflux disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroesophageal Reflux disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gastroesophageal Reflux disease R&D. The therapies under development are focused on novel approaches to treat/improve Gastroesophageal Reflux disease.

## Gastroesophageal Reflux disease Emerging Drugs Chapters

This segment of the Gastroesophageal Reflux disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Gastroesophageal Reflux disease Emerging Drugs

### Fexuprazan: Daewoong Pharmaceutical

Fexuprazan is a novel potassium-competitive acid blocker (P-CAB) developed by Daewoong, which reversibly blocks the proton pump that secretes gastric acids located in the canalicular membrane. It is a next-generation of proton pump inhibitors (PPI), which are widely used for gastroesophageal reflux disease (GERD). The drug is in preregistration stage for the treatment of gastroesophageal reflux disease.

## JP 1366: Jeil Pharmaceutical

JP 1366 belongs to the class of Antiulcers. The drug is being developed by Jeil Pharmaceuticals for the treatment of gastroesophageal reflux disease and is currently in phase II of clinical trials.

Further product details are provided in the report.....

### Gastroesophageal Reflux disease: Therapeutic Assessment

This segment of the report provides insights about the different Gastroesophageal Reflux disease drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Gastroesophageal Reflux disease

There are approx. 3+ key companies which are developing the therapies for Gastroesophageal Reflux disease. The companies which have their Gastroesophageal Reflux disease drug candidates in the most advanced stage, i.e. preregistration include, Daewoong Pharmaceutical

#### Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

## Route of Administration

Gastroesophageal Reflux disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Bispecific Antibody

Peptides

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## Gastroesophageal Reflux disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastroesophageal Reflux disease therapeutic drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroesophageal Reflux disease drugs.

## Gastroesophageal Reflux disease Report Insights

Gastroesophageal Reflux disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Gastroesophageal Reflux disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Gastroesophageal Reflux disease drugs?

How many Gastroesophageal Reflux disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastroesophageal Reflux disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastroesophageal Reflux disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Gastroesophageal Reflux disease and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Daewoong Pharmaceutical

Jeil Pharmaceutical

Effexus Pharmaceutical

Addpharma

## Key Products

Fexuprazan

JP 1366

Lansoprazole/omeprazole

AD 214

## Contents

Introduction

Executive Summary

Gastroesophageal Reflux disease: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Gastroesophageal Reflux disease – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Gastroesophageal Reflux disease companies' collaborations, Licensing, Acquisition  
-Deal Value Trends

Gastroesophageal Reflux disease Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Fexuprazan : Daewoong Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

JP 1366: Jeil Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

AD 214: Addpharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Gastroesophageal Reflux disease Key Companies

Gastroesophageal Reflux disease Key Products

Gastroesophageal Reflux disease- Unmet Needs

Gastroesophageal Reflux disease- Market Drivers and Barriers

Gastroesophageal Reflux disease- Future Perspectives and Conclusion

Gastroesophageal Reflux disease Analyst Views

Gastroesophageal Reflux disease Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Gastroesophageal Reflux disease

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Gastroesophageal Reflux disease

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Gastroesophageal Reflux disease - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/G9CE394ED4BBEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9CE394ED4BBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970